|
1
|
Levey AS, Atkins R, Coresh J, Cohen EP,
Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, et
al: Chronic kidney disease as a global public health problem:
Approaches and initiatives-a position statement from kidney disease
improving global outcomes. Kidney Int. 72:247–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zoccali C, Kramer A and Jager KJ: Chronic
kidney disease and end-stage renal disease-a review produced to
contribute to the report ‘the status of health in the European
union: Towards a healthier Europe’. NDT Plus. 3:213–224.
2010.PubMed/NCBI
|
|
3
|
Brück K, Stel VS, Gambaro G, Hallan S,
Völzke H, Ärnlöv J, Kastarinen M, Guessous I, Vinhas J, Stengel B,
et al: CKD prevalence varies across the European general
population. J Am Soc Nephrol. 27:2135–2147. 2016. View Article : Google Scholar :
|
|
4
|
Symplicity HTN-2 Investigators; Esler MD,
Krum H, Sobotka PA, Schlaich MP, Schmieder RE and Böhm M: Renal
sympathetic denervation in patients with treatment-resistant
hypertension (The Symplicity HTN-2 Trial): A randomised controlled
trial. Lancet. 376:1903–1909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Makani H, Bangalore S, Romero J,
Wever-Pinzon O and Messerli FH: Effect of renin-angiotensin system
blockade on calcium channel blocker associated peripheral edema. Am
J Med. 124:128–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dimitrow PP and Jawien M:
Anti-inflammatory effect of atorvastatin in patients with aortic
sclerosis or mild aortic stenosis independent of
hypercholesterolemia. Pharmacol Rep. 62:1250–1254. 2010. View Article : Google Scholar
|
|
7
|
Benicky J, Sanchez-Lemus E, Honda M, Pang
T, Orecna M, Wang J, Leng Y, Chuang DM and Saavedra JM: Angiotensin
II AT1 receptor blockade ameliorates brain inflammation.
Neuropsychopharmacology. 36:857–870. 2011. View Article : Google Scholar :
|
|
8
|
Kim KH and Kim WS: Chronic unilateral
chemosis following the use of amlodipine besylate. BMC Ophthalmol.
14:1242014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dai Y, Wang W, Sun Q and Tuohayi J:
Ginsenoside Rg3 promotes the antitumor activity of gefitinib in
lung cancer cell lines. Exp Ther Med. 17:953–959. 2019.PubMed/NCBI
|
|
10
|
Chang XA, Dai S, Ye ZZ and Song QH:
Treatment of facial acne vulgaris by chinese medicine combined
western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi. 37:160–164.
2017.In Chinese. PubMed/NCBI
|
|
11
|
Su L, Meng L, Chen R, Wu W, Peng B and Man
L: Acupoint application for asthma therapy in adults: A systematic
review and meta-analysis of randomized controlled trials. Forsch
Komplementmed. 23:16–21. 2016.PubMed/NCBI
|
|
12
|
Liu CY, Qin S, Liu LY, He YM, Wang HS, Wu
WZ, Chen D and Zhang C: Inhibitory effect of acupoint application
on airway remodeling and expression of TGF-β 1/Smad 3 in the lung
tissue of chronic asthma mice. Zhen Ci Yan Jiu. 42:153–158. 2017.In
Chinese. PubMed/NCBI
|
|
13
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/AKT signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha
T, Chen Q, Li C and Li Y: Carbamylated erythropoietin protects the
myocardium from acute ischemia/reperfusion injury through a
PI3K/AKT-dependent mechanism. Surgery. 146:506–514. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tramontano AF, Muniyappa R, Black AD,
Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV and El-Sherif N:
Erythropoietin protects cardiac myocytes from hypoxia-induced
apoptosis through an AKT-dependent pathway. Biochem Biophys Res
Commun. 308:990–994. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Yao Y, Xiao F, Lan X, Yu C, Zhang
Y, Jiang C, Yang J, Pei G, Li Y, et al: Administration of
dexamethasone protects mice against ischemia/reperfusion induced
renal injury by suppressing PI3K/AKT signaling. Int J Clin Exp
Pathol. 6:2366–2375. 2013.PubMed/NCBI
|
|
17
|
Xie L, Zheng X, Qin J, Chen Z, Jin Y and
Ding W: Role of PI3-kinase/AKT signalling pathway in renal function
and cell proliferation after renal ischaemia/reperfusion injury in
mice. Nephrology (Carlton). 11:207–212. 2006. View Article : Google Scholar
|
|
18
|
Matheny RW and Adam ML: Current
perspectives on AKTAKT-ivation and AKT-ions. Exp Biol Med
(Maywood). 234:1264–1270. 2009. View Article : Google Scholar
|
|
19
|
Liu L, Wu Z, Zhu D, et al: The guideline
2010 for hypertension prevention and treatment in China. 3rd
edition. 2010, http://csjfyy.com/articles/E/020/010/050.pdf.
|
|
20
|
National Research Council: The Guide for
the Care and Use of Laboratory Animals. National Academies Press;
Washington DC. revised. 1996
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Bhatt DL, Kandzari DE, O’Neill WW,
D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita
M, et al: A controlled trial of renal denervation for resistant
hypertension. N Engl J Med. 370:1393–1401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zoccali C, Tripepi R, Torino C, Tripepi G
and Mallamaci F: Moderator’s view: Ambulatory blood pressure
monitoring and home blood pressure for the prognosis, diagnosis and
treatment of hypertension in dialysis patients. Nephrol Dial
Transplant. 30:1443–1448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Azizi M, Sapoval M, Gosse P, Monge M,
Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY,
Lantelme P, et al: Optimum and stepped care standardised
antihypertensive treatment with or without renal denervation for
resistant hypertension (DENERHTN): A multicentre, open-label,
randomised controlled trial. Lancet. 385:1957–1965. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agarwal R: Pro: Ambulatory blood pressure
should be used in all patients on hemodialysis. Nephrol Dial
Transplant. 30:1432–1437. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jardine AG: Con: Ambulatory blood pressure
measurement in patients receiving haemodialysis: A sore arm and a
waste of time? Nephrol Dial Transplant. 30:1438–1441. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bansal N, McCulloch CE, Rahman M, Kusek
JW, Anderson AH, Xie D, Townsend RR, Lora CM, Wright J, Go AS, et
al: Blood pressure and risk of all-cause mortality in advanced
chronic kidney disease and hemodialysis: The chronic renal
insufficiency cohort study. Hypertension. 65:93–100. 2015.
View Article : Google Scholar
|
|
28
|
Say EA, Shields CL, Bianciotto C and
Shields JA: Chronic conjunctival chemosis from amlodipine besylate
(Norvasc). Cornea. 30:604–607. 2011. View Article : Google Scholar
|
|
29
|
Pedrinelli R, Dell’Omo G and Mariani M:
Calcium channel blockers, postural vasoconstriction and dependent
oedema in essential hypertension. J Hum Hypertens. 15:455–461.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moes AD, Hesselink DA, van den Meiracker
AH, Zietse R and Hoorn EJ: Chlorthalidone versus amlodipine for
hypertension in kidney transplant recipients treated with
tacrolimus: A randomized crossover trial. Am J Kidney Dis.
69:796–804. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Houben AJ, Burgwinkel JP and de Leeuw PW:
A novel approach to the study of human microcirculation: Reactivity
to locally applied angiotensin II in the conjunctivalmicrovascular
bed. J Hypertens. 24:2225–2230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weir MR, Rosenberger C and Fink JC: Pilot
study to evaluate a water displacement technique to compare effects
of diuretics and ACE inhibitors to alleviate lower extremity edema
due to dihy-dropyridine calcium antagonists. Am J Hypertens.
14:963–968. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu Q, Gu P, Jiang X, Jiang F, Zhuang J,
Zheng H, Yang G and Jiang S: Moderate and severe persistent
allergic rhinitis treated with acupoint application therapy of the
different intensity: A randomized controlled trial. Zhongguo Zhen
Jiu. 37:1177–1182. 2017.In Chinese.
|
|
34
|
Ooms LM, Fedele CG, Astle MV, Ivetac I,
Cheung V, Pearson RB, Layton MJ, Forrai A, Nandurkar HH and
Mitchell CA: The inositol polyphosphate 5-phosphatase, PIPP, is a
novel regulator of phosphoinositide 3-kinase-dependent neurite
elongation. Mol Biol Cell. 17:607–622. 2006. View Article : Google Scholar :
|
|
35
|
Jean S and Kiger AA: Classes of
phosphoinositide 3-kinases at a glance. J Cell Sci. 127:923–928.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scheid MP, Huber M, Damen JE, Hughes M,
Kang V, Neilsen P, Prestwich GD, Krystal G and Duronio V:
Phosphatidylinositol (3,4,5) P3 is essential but not sufficient for
protein kinase B (PKB) activation phosphatidylinositol (3,4) P2 is
required for PKB phosphorylation at Ser-473: Studies using cells
from SH2-containing inositol5-phosphatase knockout mice. J Biol
Chem. 277:9027–9035. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma K, Cheung SM, Marshall AJ and Duronio
V: PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt
phosphorylation at Thr308 and Ser473, respectively PI(3,4)P2 levels
determine PKB activity. Cell Signal. 20:684–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li H and Marshall AJ: Phosphatidylinositol
(3,4) bisphosphate-specific phosphatases and effector proteins: A
distinct branch of PI3K signaling. Cell Signal. 27:1789–1798. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Inoki K, Li Y, Zhu T, Wu J and Guan KL:
TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR
signalling. Nat Cell Biol. 4:648–657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang F, Ijuin T, Itoh T and Takenawa T:
Regulation of IGF-1/PI3K/AKT signaling by the phosphoinositide
phosphatase pharbin. J Biochem. 150:83–93. 2011. View Article : Google Scholar : PubMed/NCBI
|
